Identification of ZG16B as a prognostic biomarker in breast cancer

Haotian Lu; Chunying Shi; Xinyu Liu; Chen Liang; Chaochao Yang; Xueqi Wan; Ling Li; Ying Liu

doi:10.1515/med-2021-0004

Identification of ZG16B as a prognostic biomarker in breast cancer

Open Med (Wars). 2020 Nov 25;16(1):1-13. doi: 10.1515/med-2021-0004. eCollection 2021.

Authors

Haotian Lu¹, Chunying Shi², Xinyu Liu¹, Chen Liang¹, Chaochao Yang¹, Xueqi Wan¹, Ling Li², Ying Liu^{1

3}

Affiliations

¹ School of Basic Medicine, College of Medicine, Qingdao University, Qingdao, 266071, China.
² Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, College of Medicine, Qingdao University, Qingdao, 266071, China.
³ Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao, 266071, China.

Abstract

Zymogen granule protein 16B (ZG16B) has been identified in various cancers, while so far the association between ZG16B and breast cancer hasn't been explored. Our aim is to confirm whether it can serve as a prognostic biomarker in breast cancer. In this study, Oncomine, Cancer Cell Line Encyclopedia (CCLE), Ualcan, and STRING database analyses were conducted to detect the expression level of ZG16B in breast cancer with different types. Kaplan-Meier plotter was used to analyze the prognosis of patients with high or low expression of ZG16B. We found that ZG16B was significantly upregulated in breast cancer. Moreover, ZG16B was closely associated with foregone biomarkers and crucial factors in breast cancer. In the survival analysis, high expression of ZG16B represents a favorable prognosis in patients. Our work demonstrates the latent capacity of ZG16B to be a biomarker for prognosis of breast cancer.

Keywords: ZG16B; biomarker; breast cancer; database; prognosis.